Back to Results
First PageMeta Content
Chemistry / Organofluorides / Fixed dose combination / Microbicides / Tenofovir / Emtricitabine / Reverse-transcriptase inhibitor / Antiretroviral drug / Elvitegravir / Gilead Sciences / Pharmacology / Medicine


FOR IMMEDIATE RELEASE Tokyo, March 2, 2015 JT and Torii sign agreement to market two new tenofovir alafenamide (TAF)-based anti-HIV drugs in Japan
Add to Reading List

Document Date: 2015-03-01 21:32:08

Open Document

File Size: 66,82 KB

Share Result on Facebook

City

Tokyo / /

Company

Gilead Sciences Inc. / JT Group / Japan Japan Tobacco Inc. / Investor Relations Division Japan Tobacco Inc. / Japan Tobacco Inc. / Torii Pharmaceutical Co. Ltd. / Contacts for Japan Tobacco Inc. / Planning Department (Public Relations) Torii Pharmaceutical Co. Ltd. / /

Country

Japan / United States / /

Currency

USD / /

/

Event

FDA Phase / Business Partnership / Earnings Announcement / /

IndustryTerm

pharmaceuticals / treatment of HIV / consolidated subsidiaries / investigational products / manufacturing / regulatory applications / /

MedicalCondition

HIV infection / HIV / /

Organization

European Medicines Agency / FDA / European Union / /

Person

Dmitry Krivtsov / /

/

Position

General Manager Media / General Manager / /

Product

Emtriva / tenofovir disoproxil fumarate / Combination Tablets / Viracept / Stribild / Truvada / Viread / Stribild® / Japan / F/TAF / E/C/F/TAF / /

ProgrammingLanguage

E / C / /

URL

http /

SocialTag